Life Sciences Newsbrief – February 2011, Issue #28

Welcome to our monthly issue of the Life Sciences Newsbrief. This publication will provide you with a snapshot of developments in the Canadian and global life sciences industry along with upcoming Canadian events and thought leadership. If you need further information, please contact any of the life sciences professionals listed.

Life Sciences in Canada

Event: PwC's Canadian Life Sciences Industry Forecast 2011 Inflection Point
Wednesday, March 9, 2011 in Mississauga, Ontario

Please join us for an interactive presentation and discussion on the key findings of our fourth Canadian Life Sciences Industry Forecast 2011, a survey conducted in collaboration with BIOTECanada. This is an excellent opportunity to network, share insights, and work together to develop solutions in response to the key findings in the report.

New Podcast: Investing in Biotech

The role of Life Sciences in Canada's economy
In this episode of Strategy Talks, PwC's Calum Semple and Rozanne Kibel interview Peter Brenders, president and CEO of Ottawa-based BIOTECanada, and Gord Jans, national leader of the Life Sciences and Pharmaceuticals practice at PwC. They discuss findings from the PwC Life Science's report, Inflection Point, and how important biotechnology is to Canada's economy.

2011 Federal Budget Submission (January 24, 2011)
Members of PwC's Canadian National Tax Services team provided the Minister of Finance with income tax proposals in preparation for the 2011 federal budget. The proposals aim to improve the liquidity and competitiveness of Canadian businesses.

Thought Leadership

Pharma 2020: Supplying the future
This is the sixth paper in our Pharma 2020 series. It highlights how pharma companies will have to develop different supply chain models for different product types and patient segments, learn to use their supply chains as a means of market differentiation and source of economic value, and recognize the key role information will play flowing upstream to drive the downstream flow of products and services. In the future, companies that produce specialist medicines can either become virtual manufacturers and distributors or create service-oriented supply chains. In parallel, companies that produce mass-market medicines, including generics, can either become low-cost providers or build supply chains that service other organizations and generate a profit in their own right.

Q4 2010 Moneytree report
Venture capitalists invested $21.8 billion in 3,277 deals in 2010, an increase of 19 percent in dollars and a 12 percent rise in deals over the prior year, according to PwC's Q4 Money Tree report. This special, expanded report provides detailed results of Q4 2010 as well as comprehensive findings for full years 2009 and 2010. More detailed results, including historical data back to 1995, can be found on the MoneyTree website at www.pwcmoneytree.com.

14th Annual Global CEO Survey: 

Growth reimagined - Pharmaceuticals and Life Sciences Sector Report
This survey documents a surprising level of confidence in this environment; chief executives are nearly as confident of growth this coming year as they were in the boom years before the crisis. The survey also revealed where CEOs see growth coming in 2011, and how they are going to achieve it. This is a summary of the key findings in the Pharmaceuticals and Life Sciences sector, based on the results of this year's survey, drawn on interviews with 53 Pharma and life sciences CEOs in 23 countries.

To download the full Global CEO Survey, please visit: www.pwc.com/ceosurvey.

Webcast: Medical technology and innovation scorecard: 

Webcast: Medical technology and innovation scorecard: The race for global leadership
The presentation focused on the PwC, Medical Technology Innovation Scorecard: The race for global leadership,released on Tuesday, January 18, 2011, which evaluates the innovative capacity and capabilities of nine countries, all current or emerging leaders in medical technology in order track global shifts in medical device innovation.

The session was led by Christopher Wasden, PwC Managing Director, Strategy and Innovation, and author of the report. Also featured: Ruti Alon , Israel Life Science Industry (ILSI) Chairperson and General Partner at Pitango Venture Capital; Claudio Yarza, Assurance Partner, PwC.

The recording of this webcast will be available for 90 days.